Guro F. Giskeødegård
Bakgrunn og aktiviteter
Guro Fanneløb Giskeødegård has a PhD in Medical Technology, and is currently working as a researcher at the MR Cancer group. Her research is focused on MR spectroscopy of tissue samples and biofluids from breast and prostate cancer patients, and she has a special focus on multivariate data analysis of the MR spectra. The research goal is to identify biomarkers for improved diagnosis and treatment of breast and prostate cancer.
Vitenskapelig, faglig og kunstnerisk arbeid
Et utvalg av nyere tidsskriftspublikasjoner, kunstneriske produksjoner, bok, inklusiv bokdeler og rapport-del. Se alle publikasjoner i databasen
Tidsskriftspublikasjoner
- (2020) Metabolic alterations in tissues and biofluids of patients with prostate cancer. Current Opinion in Endocrine and Metabolic Research. vol. 10.
- (2020) Simultaneous detection of zinc and its pathway metabolites using MALDI MS imaging of prostate tissue. Analytical Chemistry. vol. 92 (4).
- (2019) Simultaneous detection of the cancer biomarkers zinc and citrate in prostate cancer tissue using mass spectrometry imaging. European urology. Supplement. vol. 18 (8).
- (2019) Acetaminophen cytotoxicity in HepG2 cells is associated with a decoupling of glycolysis from the TCA cycle, loss of NADPH production, and suppression of anabolism. Archives of Toxicology. vol. 93 (2).
- (2019) Feasibility of contrast-enhanced MRI derived textural features to predict overall survival in locally advanced breast cancer. Acta Radiologica.
- (2019) Assessing treatment response and prognosis by serum and tissue metabolomics in breast cancer patients. Journal of Proteome Research. vol. 18 (10).
- (2019) The effect of sampling procedures and day-to-day variations in metabolomics studies of biofluids. Analytica Chimica Acta. vol. 1081.
- (2019) Biomarker discovery using NMR based metabolomics of tissue. Methods in molecular biology. vol. 2037.
- (2019) Detectable biomarkers in urine for prostate cancer prognosis. European urology. Supplement. vol. 18 (8).
- (2019) Historical Biobanks in Breast Cancer Metabolomics — Challenges and Opportunities. Metabolites. vol. 9 (11).
- (2019) Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers. International Journal of Cancer. vol. 146 (1).
- (2019) Serum cytokine patterns in first half of pregnancy. Cytokine. vol. 119.
- (2019) Effect of Repeated Freeze‒Thaw Cycles on NMR-Measured Lipoproteins and Metabolites in Biofluids. Journal of Proteome Research. vol. 18 (10).
- (2018) Integrative metabolic and transcriptomic profiling of prostate cancer tissue containing reactive stroma. Scientific Reports. vol. 8:14269.
- (2018) NMR-based metabolomics of biofluids in cancer. NMR in Biomedicine. vol. 32 (10).
- (2018) Metabolite and lipoprotein responses and prediction of weight gain during breast cancer treatment. British Journal of Cancer. vol. 119 (9).
- (2017) Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. Breast Cancer Research. vol. 19.
- (2017) Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy. British Journal of Cancer. vol. 117 (11).
- (2017) Combined 18F-Fluciclovine PET/MRI shows potential for detection and characterization of high-risk prostate cancer. Journal of Nuclear Medicine. vol. 59 (5).
- (2017) Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy. Metabolomics. vol. 13:37.